Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

about

Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

Item

http://www.wikidata.org/entity/Q49335971

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

@en

Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

@nl

type

Item

label

Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

@en

Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

@nl

altLabel

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease

@en

prefLabel

Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

@en

Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

@nl

P1476

Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

@en

P2860

Clinical spectrum of levodopa-induced complications.

Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.

Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?

Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.

Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-en

Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

P304

1756285617737728

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756285617737728

http://www.w3.org/2001/XMLSchema#string

P4011

54bad333ef1938ec9df61c995aa8994c6c15a420

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

C. Colin Singer

Jason Margolesky

P577

2017-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29399046

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

levodopa

P932

5784558

http://www.w3.org/2001/XMLSchema#string